A Microdose Study to Describe the Intravenous Pharmacokinetics of [14C]-GSK2239633 in Healthy Male Subjects.

A Microdose Study to Describe the Intravenous Pharmacokinetics of [14C]-GSK2239633 in Healthy Male Subjects. - [14C]-GSK633 microdose study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON35064

Enrollment

Registered

2009-12-28

Start date

2010-02-14

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

Active substance: GSK2239633 and [14C]-GSK2239633 Activity: CCR4 antagonist selectively blocking recruitment of TH2 cells which are effectors cells for allergic inflammation Indication: Asthma Stre

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - healthy male volunteers - age between 18 and 50 years - body weight is 50 kg or more and BMI is between 18.5 and 29.9 kg/m2 - non smoker (have not smoked for at least 6 months and/or have not smoked for a period of 10 years with a maximum of 10 cigarettes or equivalent per day or a period of 5 years with a maximum of 20 cigarettes or equivalent per day prior to study drug administration

Exclusion criteria

Exclusion criteria: Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics : plasma and urine GSK2239633 concentrations, pharmacokinetic parameters Radiokinetics : total radioactivity in plasma and urine	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)